NAS:ARWR (USA) Also Trade In: Germany Mexico UK

Arrowhead Pharmaceuticals Inc $ 58.56 1.84 (3.24%)

On watch
Volume:
1,642,072
Avg Vol (1m):
1,820,561
Market Cap $:
5.99 Bil
Enterprise Value $:
5.72 Bil
P/E (TTM):
0.00
P/B:
12.15
Warning! GuruFocus has detected 2 Severe warning signs with ARWR. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)

ARWR News and Headlines - Arrowhead Pharmaceuticals Inc

GuruFocus Articles Total 6
  • 1

Companies in race to find treatment for genetic disease that can cause lung and liver disease

Adopting the theory that two heads are better than one, a pair of former biotech rivals are teaming up to take on a third company that has a head start in the search for a treatment for a genetic disease that can cause lung and liver disease.

Alnylam Pharmaceuticals (ALNY) and Dicerna Pharmaceuticals (DRNA) have joined forces to challenge Arrowhead Pharmaceuticals (ARWR) as well as two other companies working on a treatment, Intellia Therapeutics (NTLA) and Vertex Pharmaceuticals (VRTX).

Evidently, investors believe that a rising tide lifts all boats since shares of all five companies were up Monday, with Arrowhead

147 Views    Barry Cohen    2020-04-06 21:26
Company posts earnings and revenue beat, raises guidance

Health care conglomerate Johnson & Johnson (JNJ) reported strong third-quarter earnings before the opening bell on Tuesday, sending shares higher.

The New Brunswick, New Jersey-based company, which also produces consumer goods, posted adjusted earnings of $2.05 per share, topping Refinitiv’s estimates of $2.03. Revenue grew 3.6% from the prior-year quarter to $20.35 billion, beating expectations of $20.05 billion.

792537.png

Johnson & Johnson’s pharmaceuticals segment saw 6.7% revenue growth to $10.3 billion. While worldwide sales of cancer drug Darzalex, which reached $498 million, missed expectations of $538.7 million, sales of Stelara, which treats plaque psoriasis, came

250 Views    Sydnee Gatewood    2018-10-16 16:29
Johnson & Johnson seems undervalued given latest developments

In volatile markets, who doesn’t love stable stocks? Johnson & Johnson (JNJ) is one such play that investors constantly have on their watchlist, owing to the "recession-proof" nature of the investment, as some analysts like to term it.

While it isn’t challenging to pick winners in a bull and trending market, picking a northward-marching investment in a volatile and shaky market can be quite the hassle.

To save the day comes Johnson & Johnson. While the overall macroeconomic condition of the economy is quite stable, with interest rates going toward normal pre-crisis numbers along with increasing GDP

130 Views    Shubham Jaipuria    2018-10-08 21:05

The biopharmaceutical firm, Arrowhead Research (ARWR), has spent years finding treatment to various deadly diseases through the RNAi therapeutics platform, and just recently it has announced that it wants to acquire the RNAi assets from Novartis (NVS) to take a giant leap in this research and developmental platform.Â

What is the RNAi Therapy platform?

In the current therapy procedures being followed by pharma companies, the therapy works on generation of monoclonal antibodies which binds to the disease causing proteins to deactivate them. On the other hand, this exclusive RNAi therapy procedure tries to kill the disease causing proteins by

510 Views    Market News Forum    2015-03-09 18:39

According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below:

Natural Resources Partners LP (NRP): Chairman and CEO, 10% Owner Corbin J Jr Robertson Bought 270,383 Shares

Chairman and CEO, 10% Owner of Natural Resources Partners LP (NRP) Corbin J Jr Robertson bought 270,383 shares on 10/10/2014 at an average price of $12.04. Natural Resource Partners L.P., is a limited partnership formed in April 2002. Natural Resources Partners Lp has a market cap of $1.34 billion; its shares

1038 Views    GuruFocus    2014-10-20 14:40
According to [url=http://www.gurufocus.com/InsiderBuy.php]GuruFocus Insider Data[/url], these are the largest CFO buys during the past week. SVP and CFO of Jazz Pharmaceuticals Inc. (JAZZ) Kathryn E Falberg bought 50,000 shares on 08/31/2010 at an average price of $8.72. Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Jazz Pharmaceuticals Inc. has a market cap of $374.2 million; its shares were traded at around $9.71 with a P/E ratio of 23.7 and P/S ratio of 2.9. Jazz Pharmaceuticals, Inc. announced financial results for the second quarter
1989 Views    guruek    2010-09-05 04:32

Headlines Total 41
  • 1

2020-10-22 $ 58.56 (3.24%)
5:15pm
2020-10-15 $ 48.85 (9.87%)
5:00pm
2020-10-13 $ 46.52 (0.28%)
10:20am
2020-10-12 $ 46.39 (0.74%)
2:21am
2020-09-23 $ 44.64 (1.92%)
9:34am
2020-09-16 $ 47.43 (40.33%)
11:48am
2020-09-11 $ 33.21 (-5.65%)
5:24am
2020-08-31 $ 42.24 (0.64%)
3:30pm
2020-08-19 $ 44.54 (-2.54%)
11:38pm
2020-08-17 $ 45.7 (8.78%)
11:08am
2020-08-14 $ 42.01 (-1.64%)
6:15pm
2020-07-08 $ 45.25 (2.28%)
10:13am
2020-06-29 $ 42.6 (-1.55%)
1:21am
2020-06-26 $ 43.27 (2.46%)
6:15pm
2020-06-12 $ 32.73 (3.64%)
1:23pm
2020-06-02 $ 32.77 (-1.62%)
12:35pm
2020-05-24
10:10am
2020-05-19 $ 36.49 (-4.58%)
1:08pm
7:02am
2020-05-08 $ 34.14 (-2.82%)
11:39am
2020-04-30 $ 34.43 (-5.75%)
7:52am
2020-04-23 $ 36.94 (0.87%)
7:15pm
2020-03-19 $ 20.56 (-6.42%)
11:00pm
2020-01-24 $ 46.21 (-2.88%)
6:15pm
2020-01-09 $ 59.8 (0.37%)
6:15pm
2019-12-27 $ 64.93 (-3.08%)
4:15pm
2019-12-14 $ 66.46 (-1.28%)
6:15pm
2019-12-05 $ 66.46 (-3.2%)
6:15pm
2019-11-02 $ 41.48 (3.57%)
8:15pm
2019-10-12 $ 32.55 (1.72%)
7:15pm
2019-09-28 $ 26.96 (-1.14%)
9:15pm
2019-09-25 $ 28.08 (-2.77%)
9:15pm
2018-11-30 $ 14.52 (-0.62%)
7:01am
2015-03-09 $ 7.4 (-4.52%)
1:39pm
2011-02-10 $ 8.9 (%)
4:23pm
2010-05-13 $ 15.1 (2.03%)
4:18pm
2010-02-11 $ 5.8 (-6.45%)
5:14pm
2009-12-23 $ 5.1 (-1.54%)
6:17pm
2009-08-11 $ 4.5 (4.65%)
8:26pm
2009-05-15 $ 4.9 (-10.91%)
10:06am
2009-02-10 $ 7.9 (-4.82%)
10:07pm
Total 41
  • 1